Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648

K. Kato, J. Ajani, Y. Doki, J. Xu, L. Wyrwicz, S. Motoyama, T. Ogata, H. Kawakami, C.-H. Hsu, A. Adenis, F. el Hajbi, M. Di Bartolomeo, M. Ignez Braghiroli, E. Holtved, T. Makino, M. Blum Murphy, J. Zhang, P. Sharma, B. He, M. Lei, Y. Matsumura, Y. Kitagawa, I. Chau

Open source

DOI: 10.1016/j.annonc.2026.08.001
Published: 2026-08
Container: Annals of Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2026.08.001,
  title = {Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648},
  author = {K. Kato and J. Ajani and Y. Doki and J. Xu and L. Wyrwicz and S. Motoyama and T. Ogata and H. Kawakami and C.-H. Hsu and A. Adenis and F. el Hajbi and M. Di Bartolomeo and M. Ignez Braghiroli and E. Holtved and T. Makino and M. Blum Murphy and J. Zhang and P. Sharma and B. He and M. Lei and Y. Matsumura and Y. Kitagawa and I. Chau},
  year = {2026},
  journal = {Annals of Oncology},
  doi = {10.1016/j.annonc.2026.08.001},
  url = {https://doi.org/10.1016/j.annonc.2026.08.001}
}

RIS

TY  - JOUR
TI  - Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648
AU  - K. Kato
AU  - J. Ajani
AU  - Y. Doki
AU  - J. Xu
AU  - L. Wyrwicz
AU  - S. Motoyama
AU  - T. Ogata
AU  - H. Kawakami
AU  - C.-H. Hsu
AU  - A. Adenis
AU  - F. el Hajbi
AU  - M. Di Bartolomeo
AU  - M. Ignez Braghiroli
AU  - E. Holtved
AU  - T. Makino
AU  - M. Blum Murphy
AU  - J. Zhang
AU  - P. Sharma
AU  - B. He
AU  - M. Lei
AU  - Y. Matsumura
AU  - Y. Kitagawa
AU  - I. Chau
PY  - 2026
JO  - Annals of Oncology
DO  - 10.1016/j.annonc.2026.08.001
UR  - https://doi.org/10.1016/j.annonc.2026.08.001
ER  -

APA

Kato, K., Ajani, J., Doki, Y., Xu, J., Wyrwicz, L., Motoyama, S., Ogata, T., Kawakami, H., Hsu, C., Adenis, A., Hajbi, F. E., Bartolomeo, M. D., Braghiroli, M. I., Holtved, E., Makino, T., Murphy, M. B., Zhang, J., Sharma, P., He, B., Lei, M., Matsumura, Y., Kitagawa, Y., & Chau, I. (2026). Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648. Annals of Oncology. https://doi.org/10.1016/j.annonc.2026.08.001

Source records

crossref · retrieved 2026-09-25T14:41:47.619Z